# Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)

> **NCT01704781** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bionor Immuno AS** · enrollment: 36 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Lenalidomide placebo
- **DRUG:** Vacc-4X
- **DRUG:** rhuGM-CSF

## Key facts

- **NCT ID:** NCT01704781
- **Lead sponsor:** Bionor Immuno AS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2017-03-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01704781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01704781, "Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01704781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*